<p>添加</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>作為您在 Google 上的首選新聞來源</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>立即添加</p>
<p>醫療設備製造商 Coloplast A/S (COLO-B.CO) 週二報告其第二季度虧損，相比於去年同期的盈利，主要受到與 Kerecis 相關的大額減值損失的影響，儘管收入有所增長。此外，該公司重申了 2026 財年的展望。</p>
<p>在哥本哈根，股價上漲約 0.37%，交易價格為 402.00 丹麥克朗。</p>
<p>在第二季度，公司錄得淨虧損 9.71 億丹麥克朗，而去年同期的盈利為 9.12 億丹麥克朗。每股虧損為 4.31 丹麥克朗，而去年同期的盈利為 4.05 丹麥克朗。</p>
<p>最新的業績主要受到與 Kerecis 相關的 30.3 億丹麥克朗的特殊減值損失的影響，因為預計皮膚替代品的市場復甦速度較慢。</p>
<p>調整後的每股收益為 6.16 丹麥克朗，而去年同期為 4.34 丹麥克朗。</p>
<p>在特殊項目之前的營業利潤或 EBIT 較去年下降 4%，至 18.2 億丹麥克朗。調整後的 EBITDA 下降 3%，至 21.7 億丹麥克朗。</p>
<p>調整後的 EBIT 利潤率為 26%，而去年為 27%。</p>
<p>Coloplast 在第二季度實現了 6% 的有機增長和 6% 的 EBIT 增長（以固定匯率計算）。慢性護理和介入性泌尿學表現強勁，而傷口與組織修復的季度表現則面臨挑戰。</p>
<p>儘管受到貨幣的 4 個百分點的負面影響，收入仍增長 2%，從去年的 69.3 億丹麥克朗增至 70.8 億丹麥克朗。有機增長為 6%。</p>
<p>此外，公司表示將支付每股 5.00 丹麥克朗的半年期中期股息，總股息支付為 11.3 億丹麥克朗。</p>
<p>展望 2026 財年，Coloplast 表示預計收入增長約為 3%，貨幣的負面影響為 2% 至 3 個百分點，有機收入增長為 5% 至 6%，調整後的 EBIT 在固定匯率下增長約 5%。</p>
<p>年度業績將包括約 31 億丹麥克朗的特殊項目，反映 Kerecis 的減值損失。</p>
<p>有關更多盈利新聞、盈利日曆和股票盈利信息，請訪問 rttnews.com。</p>
<p>如有意見和反饋，請聯繫：editorial@rttnews.com</p>
<p>商業新聞</p>

天弘國證生物醫藥ETF

鵬華上證科創板生物醫藥ETF

<p>Coloplast A/S 報告第二季度虧損 9.71 億丹麥克朗，較去年 9.12 億克朗的利潤下降，主要由於與 Kerecis 相關的 30.3 億克朗的減值損失。儘管如此，收入仍增長 2%，達到 70.8 億克朗，且有機增長為 6%。該公司重申了 2026 財年的展望，預計收入增長 3%，調整後的 EBIT 增長約 5%。將支付每股 5.00 克朗的半年期中期股息</p>

<p>Add</p>
<div class="lb-trans"><p>添加</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png" alt="" original-src="https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>as your preferred news source on Google</p>
<div class="lb-trans"><p>作為您在 Google 上的首選新聞來源</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png" alt="" original-src="https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>Add Now</p>
<div class="lb-trans"><p>立即添加</p>
</div><p>Coloplast A/S (COLO-B.CO), a medical devices manufacturer, reported Tuesday a loss in its second quarter, compared to prior year's profit, mainly hurt by a hefty impairment loss related to Kerecis, despite higher revenues. Further, the firm reaffirmed fiscal 2026 outlook.</p>
<div class="lb-trans"><p>醫療設備製造商 Coloplast A/S (COLO-B.CO) 週二報告其第二季度虧損，相比於去年同期的盈利，主要受到與 Kerecis 相關的大額減值損失的影響，儘管收入有所增長。此外，該公司重申了 2026 財年的展望。</p>
</div><p>In Copenhagen, the shares were gaining around 0.37 percent, trading at 402.00 Danish kroner.</p>
<div class="lb-trans"><p>在哥本哈根，股價上漲約 0.37%，交易價格為 402.00 丹麥克朗。</p>
</div><p>In the second quarter, the company recorded net loss of 971 million Danish kroner, compared to last year's profit of 912 million kroner. Loss per share was 4.31 kroner, compared to profit of 4.05 kroner a year ago.</p>
<div class="lb-trans"><p>在第二季度，公司錄得淨虧損 9.71 億丹麥克朗，而去年同期的盈利為 9.12 億丹麥克朗。每股虧損為 4.31 丹麥克朗，而去年同期的盈利為 4.05 丹麥克朗。</p>
</div><p>The latest results were mainly hurt by a special impairment loss of 3.03 billion kroner related to Kerecis as a result of the slower market recovery now anticipated in the skin substitutes out-patient setting.</p>
<div class="lb-trans"><p>最新的業績主要受到與 Kerecis 相關的 30.3 億丹麥克朗的特殊減值損失的影響，因為預計皮膚替代品的市場復甦速度較慢。</p>
</div><p>Adjusted earnings per share were 6.16 kroner, compared to 4.34 kroner a year ago.</p>
<div class="lb-trans"><p>調整後的每股收益為 6.16 丹麥克朗，而去年同期為 4.34 丹麥克朗。</p>
</div><p>Operating profit or EBIT before special items dropped 4 percent from last year to 1.82 billion kroner. Adjusted EBITDA fell 3 percent to 2.17 billion kroner.</p>
<div class="lb-trans"><p>在特殊項目之前的營業利潤或 EBIT 較去年下降 4%，至 18.2 億丹麥克朗。調整後的 EBITDA 下降 3%，至 21.7 億丹麥克朗。</p>
</div><p>The adjusted EBIT margin was 26 percent, against 27 percent last year.</p>
<div class="lb-trans"><p>調整後的 EBIT 利潤率為 26%，而去年為 27%。</p>
</div><p>Coloplast delivered Q2 organic growth of 6 percent and 6 percent EBIT growth1 in constant currencies. Strong quarter in Chronic Care and Interventional Urology, challenging quarter in Wound &amp; Tissue Repair.</p>
<div class="lb-trans"><p>Coloplast 在第二季度實現了 6% 的有機增長和 6% 的 EBIT 增長（以固定匯率計算）。慢性護理和介入性泌尿學表現強勁，而傷口與組織修復的季度表現則面臨挑戰。</p>
</div><p>Revenue grew 2 percent to 7.08 billion kroner from 6.93 billion kroner last year, despite 4 percent points negative impact from currencies. Organic growth was 6 percent.</p>
<div class="lb-trans"><p>儘管受到貨幣的 4 個百分點的負面影響，收入仍增長 2%，從去年的 69.3 億丹麥克朗增至 70.8 億丹麥克朗。有機增長為 6%。</p>
</div><p>Further, the company said it will pay a half-year interim dividend of 5.00 kroner per share, for a total dividend pay-out of 1.13 billion kroner.</p>
<div class="lb-trans"><p>此外，公司表示將支付每股 5.00 丹麥克朗的半年期中期股息，總股息支付為 11.3 億丹麥克朗。</p>
</div><p>Looking ahead for fiscal 2026, Coloplast said it continues to project revenue growth at around 3 percent, with 2 percent to 3 percent-points negative impact from currencies, organic revenue growth at 5 percent to 6 percent, and adjusted EBIT growth in constant currencies of around 5 percent.</p>
<div class="lb-trans"><p>展望 2026 財年，Coloplast 表示預計收入增長約為 3%，貨幣的負面影響為 2% 至 3 個百分點，有機收入增長為 5% 至 6%，調整後的 EBIT 在固定匯率下增長約 5%。</p>
</div><p>The annual results would include special items of around 3.1 billion kroner, reflecting the Kerecis impairment loss.</p>
<div class="lb-trans"><p>年度業績將包括約 31 億丹麥克朗的特殊項目，反映 Kerecis 的減值損失。</p>
</div><p>For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.</p>
<div class="lb-trans"><p>有關更多盈利新聞、盈利日曆和股票盈利信息，請訪問 rttnews.com。</p>
</div><p>For comments and feedback contact: editorial@rttnews.com</p>
<div class="lb-trans"><p>如有意見和反饋，請聯繫：editorial@rttnews.com</p>
</div><p>Business News</p>
<div class="lb-trans"><p>商業新聞</p>
</div>

Coloplast Slips To Loss In Q2 On Hefty Charge, Revenues Rise; Confirms FY26 Outlook

rttnews

BlackRock, Inc.

方正富邦中證醫藥及醫療器械創新ETF

科創醫藥ETF工銀

醫療業 ETF - SPDR

標普健康醫療設備 ETF - SPDR

醫療器械ETF永贏

美國制藥 ETF - iShares

招商中證全指醫療器械ETF

華夏上證科創板生物醫藥ETF

美國醫藥設備 ETF - iShares

標普全球醫療股指數 ETF - iShares

醫藥突破 ETF - ALPS

平安中證醫療創新ETF

醫療業 ETF - Vanguard

華夏中證全指醫療器械ETF

Coloplast A/S Class B

Coloplast 因鉅額費用在第二季度轉為虧損，但收入有所上升；確認 2026 財年的展望